Heightened levels of circulating 20S proteasome in critically ill patients

European Journal of Clinical Investigation

Volumn 35, Issue 6, 2005, Pages 399-403

  Roth, G A ^a   Moser, B ^b   Krenn, C ^a   Roth Walter, F ^a   Hetz, H ^a   Richter, S ^a   Brunner, M ^a   Jensen Jarolim, E ^a   Wolner, E ^a   Hoetzenecker, K ^a   Boltz Nitulescu, G ^a   Ankersmit, Hendrik Jan ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

20S proteasome; Activation; Autoimmunity; Leucocyte; Sepsis; Trauma

Indexed keywords

INOTROPIC AGENT; PROTEASOME; UBIQUITIN;

ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER; CASE CONTROL STUDY; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CRITICAL ILLNESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALIZATION; HUMAN; INJURY SCALE; LEUKOCYTE ACTIVATION; MALE; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; T LYMPHOCYTE; TRAFFIC ACCIDENT; UNIVERSITY HOSPITAL; VOLUNTEER;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; CRITICAL ILLNESS; CYSTEINE ENDOPEPTIDASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; WOUNDS AND INJURIES;

EID: 20444477186     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01508.x     Document Type: Article

References (23)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry CH. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 1996;87:4261-75.
3. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-51.
4. Roth G, Moser B, Krenn C, Brunner M, Haisjackl M, Almer G et al. Susceptibility to programmed cell death in T lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. Biochem Biophys Res Commun 2003;5:840-6.
5. Kotani J, Avallone NJ, Lin E, Goshima M, Gandhi K, Lowry SF et al. Fas-mediated neutrophil apoptosis and associated A1 protein expression during systemic inflammation are regulated independently of both tumor necrosis factor receptors. Shock 2003;19:201-7.
6. Marsik C, Halama T, Cardona F, Wlassits W, Mayr F, Pleiner J et al. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 2003;20:493-6.
7. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001;233:9-17.
8. Reid WD, MacGowan NA. Respiratory muscle injury in animal models and humans. Mol Cell Biochem 1998;179:63-80.
9. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R et al. A gated channel into the proteasome core particle. Nat Struct Biol 2000;7:1062-7.
10. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998;92:367-80.
11. Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H et al. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 1996;381:166-8.
12. Preckel T, Fung-Leung WP, Cai Z, Vitiello A, Salter-Cid L, Winqvist O et al. Impaired immunoproteasome assembly and immune responses in PA28-/- mice. Science 1999;286:162-5.
13. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, Burmester GR et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 2002;29:2045-52.
14. Taio G, Fagan JM, Samuels N, James JH, Liebermann M, Fischer JE et al. Sepsis is associated with increased mRNA of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 1997;99:163-8.
15. Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L et al. Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Meth 2002;260:183-93.
16. Walsh DS, Siritongtaworn P, Pattanapanyasat K, Thavichaigarn P, Kongcharoen P, Jiarakul N et al. Lymphocyte activation after non-thermal trauma. Br J Surg 2000;87:223-7.
17. Siegel RM, Muppidi J, Roberts M, Porter M, Wu Z. Death receptor signaling and autoimmunity. Immunol Res 2003;27:499-512.
18. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
19. Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 1993;121:215-23.
20. Du J, Hu Z, Mitch WE. Molecular mechanisms activating muscle protein degradation in chronic kidney disease and other catabolic conditions. Eur J Clin Invest 2005;35:157-63.
21. Hobler SC, Williams A, Fischer D, Wang JJ, Sun X, Fischer JE et al. Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis. Am J Physiol Regul Integr Comp Physiol 1999;277:434-40.
22. Qureshi N, Perera PY, Shen J, Zhang G, Lenschat A, Splitter G et al. The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J Immunol 2003;171:1515-25.
23. Fischer D, Gang G, Pritts T, Hasselgren PO. Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo. Biochem Biophys Res Commun 2000;270:215-21.